Choice of conservative therapeutic modalities for hepatocellular carcinoma

Yasushi Shingai, Keijiro Ando, Yuji Kado, Mitsuru Yasunaga, Hiroshi Nawata, Keiki Ogino, Kiwamu Okita, Tadayoshi Takemoto

Research output: Contribution to journalArticlepeer-review


309 patients with hepatocellular carcinoma (HCC) were studied to discuss the efficacy of, and the appropriate selection of conservative therapeutic modalities for HCC. These modalities included partial hepatectomy (22 cases), transcatheter arterial embolization (TAE) (35 cases) lipiodolization (32 cases), one-shot therapy (140 cases), and no or only systemic chemotherapy (80 cases). Eleven patients also underwent IFN-y therapy. And patients were stratified into 3 to 4 grades according to clinical stage (CS), tumor stage (TS) and portal invasion (Vp). Active treatments such as TAE, lipiodolization and one-shot therapy are effective in CS I to II, TS I to II and Vp 0 to 3. On the other hand, these treatments are of little prospect of life-prolongation in CS III, TS III and/or Vp 4. IFN-y can be expected as an appropriate systemic treatment because of the elevated NK activity following its administration.

Original languageEnglish
Pages (from-to)1568-1577
Number of pages10
Issue number11
Publication statusPublished - 1986

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Choice of conservative therapeutic modalities for hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this